Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous dendritic cell vaccine after curative resection for stage IV colorectal cancer
2015-000894-11Phase 2Active
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Dec 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous dendritic cell vaccine and aldesleukin in colorectal cancer (CRC) and rectal adenocarcinoma, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Safety and Immunological efficacy. Started Dec 2017; status: active.
02
Drugs
autologous dendritic cell vaccinealdesleukin
03
Conditions
colorectal cancer (CRC)rectal adenocarcinoma
Beyond the preview
Go deeper on 2015-000894-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000894-11.